Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
BackgroundOvarian cancer (OV) is the second most prevalent gynecological tumor. Recurrent pregnancy loss (RPL) refers to two or more spontaneous abortions. However, the molecular mechanisms underlying both OV and RPL remain poorly understood. This article focuses on the exploration of the common genetic characteristics of OV and RPL and their molecular mechanisms.MethodsThe 71 differentially expressed genes associated with RPL and 1427 genes associated with OV survival were analyzed, among which 7 common genes were both important in the pathogenesis of RPL and OV. Then stepAIC analysis was performed to simplify the model and decrease the number of genes, which yielded a final set of 5 prognostic genes with coefficients to construct a prognostic risk scoring system. Univariate and multivariate Cox analyses were conducted to verify the independent prognostic factor for OV patients. GSEA and GO analysis results showed enriched biological pathways in the high/low risk groups, thereby revealing their biological characteristics. The effect of immunotherapy is better in LR patients. There was a significantly higher enrichment score of stemness and higher tumor aneuploidy score in the HR group.ResultsA five-gene prognostic risk model provided a more accurate prognosis for OV, and this prognostic score system was validated using two external cohorts. The risk score was an independent prognostic index for OV patients. Based on levels of ICs, immune cell infiltration, and predicted response, low risk OV patients were more likely to benefit from immunotherapies.ConclusionsThe 5-gene risk model can predict the prognosis of OV patients, which can draw the attention of clinicians and help stratify patients into high and low risk groups for management.
BackgroundOvarian cancer (OV) is the second most prevalent gynecological tumor. Recurrent pregnancy loss (RPL) refers to two or more spontaneous abortions. However, the molecular mechanisms underlying both OV and RPL remain poorly understood. This article focuses on the exploration of the common genetic characteristics of OV and RPL and their molecular mechanisms.MethodsThe 71 differentially expressed genes associated with RPL and 1427 genes associated with OV survival were analyzed, among which 7 common genes were both important in the pathogenesis of RPL and OV. Then stepAIC analysis was performed to simplify the model and decrease the number of genes, which yielded a final set of 5 prognostic genes with coefficients to construct a prognostic risk scoring system. Univariate and multivariate Cox analyses were conducted to verify the independent prognostic factor for OV patients. GSEA and GO analysis results showed enriched biological pathways in the high/low risk groups, thereby revealing their biological characteristics. The effect of immunotherapy is better in LR patients. There was a significantly higher enrichment score of stemness and higher tumor aneuploidy score in the HR group.ResultsA five-gene prognostic risk model provided a more accurate prognosis for OV, and this prognostic score system was validated using two external cohorts. The risk score was an independent prognostic index for OV patients. Based on levels of ICs, immune cell infiltration, and predicted response, low risk OV patients were more likely to benefit from immunotherapies.ConclusionsThe 5-gene risk model can predict the prognosis of OV patients, which can draw the attention of clinicians and help stratify patients into high and low risk groups for management.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.